tradingkey.logo

Nautilus Biotechnology Inc

NAUT
查看詳細走勢圖
1.980USD
+0.040+2.06%
收盤 12/22, 16:00美東報價延遲15分鐘
250.08M總市值
虧損本益比TTM

Nautilus Biotechnology Inc

1.980
+0.040+2.06%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+2.06%

5天

+4.21%

1月

-11.61%

6月

+177.04%

今年開始到現在

+17.86%

1年

+12.50%

查看詳細走勢圖

TradingKey Nautilus Biotechnology Inc股票評分

單位: USD 更新時間: 2025-10-27

操作建議

當前估值合理,機構持股佔比非常高,近一個月多位分析師給出公司評級為強力買入。最高目標價max_target_price。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Nautilus Biotechnology Inc評分

相關信息

行業排名
210 / 501
全市場排名
370 / 4682
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 2 分析師
強力買入
評級
2.500
目標均價
+23.15%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Nautilus Biotechnology Inc亮點

亮點風險
Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.
利潤高增長
公司淨利潤處於行業前列,最新年度總收入0.00美元
估值高估
公司最新PE估值-2.59,處於3年歷史高位
機構減倉
最新機構持股57.12M股,環比減少6.05%
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉,最新持倉619.91K股
活躍度降低
近期活躍度降低,過去20天平均換手率0.45

Nautilus Biotechnology Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Nautilus Biotechnology Inc簡介

Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.
公司代碼NAUT
公司Nautilus Biotechnology Inc
CEOPatel (Sujal)
網址https://www.nautilus.bio/

常見問題

Nautilus Biotechnology Inc(NAUT)的當前股價是多少?

Nautilus Biotechnology Inc(NAUT)的當前股價是 1.980。

Nautilus Biotechnology Inc 的股票代碼是什麼?

Nautilus Biotechnology Inc的股票代碼是NAUT。

Nautilus Biotechnology Inc股票的52週最高點是多少?

Nautilus Biotechnology Inc股票的52週最高點是2.540。

Nautilus Biotechnology Inc股票的52週最低點是多少?

Nautilus Biotechnology Inc股票的52週最低點是0.620。

Nautilus Biotechnology Inc的市值是多少?

Nautilus Biotechnology Inc的市值是250.08M。

Nautilus Biotechnology Inc的淨利潤是多少?

Nautilus Biotechnology Inc的淨利潤為-70.78M。

現在Nautilus Biotechnology Inc(NAUT)的股票是買入、持有還是賣出?

根據分析師評級,Nautilus Biotechnology Inc(NAUT)的總體評級為--,目標價格為2.500。

Nautilus Biotechnology Inc(NAUT)股票的每股收益(EPS TTM)是多少

Nautilus Biotechnology Inc(NAUT)股票的每股收益(EPS TTM)是-0.498。
KeyAI